GSK2850163

GSK2850163

G650135-5mg

5mg

≥98%

-20°C储存

超低温冰袋运输

GSK2850163 is a novel inhibitor of inositol-requiring enzyme-1 alpha ( IRE1α ) which can inhibit IRE1α kinase activity and RNase activity with IC 50 s of 20 and 200 nM, respectively. In Vitro GSK2850163 is a novel inhibitor of inositol-requiring enzyme-1 alpha (IRE1α) which can inhibit IRE1α kinase activity and RNase activity with IC 50 s of 20 and 200 nM, respectively. The increased autophosphorylation of IRE1α could be reduced in a dose-dependent manner by GSK2850163. Increasing concentrations of GSK2850163 are capable of reducing the increased XBP 1 transcriptional activity. Two additional kinases are weakly inhibited by GSK2850163: Ron (IC 50 =4.4 μM) and FGFR1 V561M (IC 50 =17 μM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Oil IC50& Target:IC50: 20 nM (IRE1α kinase activity), 200 nM (IRE1α RNase activity)

GSK2850163 是一种新型的肌醇需要酶-1α（IRE1α）抑制剂，可抑制 IRE1α 激酶活性和 RNase 活性，IC 50 s 分别为 20 和 200 nM。

2121989-91-9

C24H29Cl2N3O

446.41 g/mol

73291790

CC1=CC=C(C=C1)CNC(=O)N2CCC[C@@]3(C2)CCN(C3)CC4=CC(=C(C=C4)Cl)Cl

(5R)-2-[(3,4-dichlorophenyl)methyl]-N-[(4-methylphenyl)methyl]-2,7-diazaspiro[4.5]decane-7-carboxamide

1S/C24H29Cl2N3O/c1-18-3-5-19(6-4-18)14-27-23(30)29-11-2-9-24(17-29)10-12-28(16-24)15-20-7-8-21(25)22(26)13-20/h3-8,13H,2,9-12,14-17H2,1H3,(H,27,30)/t24-/m1/s1

YFDASBFQKMHSSJ-XMMPIXPASA-N

CC1=CC=C(C=C1)CNC(=O)N2CCCC3(C2)CCN(C3)CC4=CC(=C(C=C4)Cl)Cl

73291790

DMSO : 67.5 mg/mL (151.21 mM; Need ultrasonic) Ethanol : 50 mg/mL (112.00 mM; Need ultrasonic)

1

2

4

445.169 Da

445.169 Da

35.600 Ų

30

0

583.000

0

1

4.900